Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from LBT Innovations Limited ( (AU:CC5) ).
Clever Culture Systems Ltd, a leader in AI microbiology automation, has released an updated company presentation, highlighting its advanced technology, the APAS® Independence. This development underscores the company’s commitment to revolutionizing microbial quality control in pharmaceutical manufacturing and enhancing its market presence in clinical diagnostics, potentially impacting stakeholders positively by expanding its reach through exclusive distribution partnerships.
More about LBT Innovations Limited
Clever Culture Systems (CCS) is a leader in AI microbiology automation, providing intelligent automation solutions to microbiology laboratories. Based in Adelaide, South Australia, the company has developed the Automated Plate Assessment System (APAS® Independence), which uses artificial intelligence and machine learning to automate the imaging, analysis, and interpretation of microbiology culture plates. This technology is the only US FDA-cleared AI technology for automated culture plate reading and is sold to microbiology laboratories in the pharmaceutical manufacturing sector and clinical laboratories for infectious disease diagnostics. Thermo Fisher Scientific, Inc is the exclusive distributor of the APAS® Independence to clinical customers in the US and selected European countries.
Average Trading Volume: 751,716
Technical Sentiment Signal: Hold
Current Market Cap: A$30.03M
See more data about CC5 stock on TipRanks’ Stock Analysis page.